SUBMIT MANUSCRIPT

Donnish Journal of Biomedical Research (DJBR)

August 2016 Vol. 3(2), pp. 006-012

Copyright 2016 Donnish Journals




Original Research Paper


Impact of IL28B Gene Polymorphism and HOMA-IR on Response to Pegylated-interferon and Ribavirin Therapy on Chronic HCV-4 Patients


Ola S. Mohamed1, Kamal A. El Atraby2, Reham A. Gabry3*, Khadiga K. EL Gohary4, Nahla S. Kotb5 and Amany A. Abou-Ella6

1Biochemistry Department, Faculty of Pharmacy, AL-Azhar University, Egypt.
2General Medicine and Liver Disease, National Hepatology and Tropical Medicine Research Institute, Egypt.
3Pharmacy Department, National Hepatology and Tropical Medicine Research Institute, Egypt.
4Biochemistry Department, El Sahel Teaching Hospital, Egypt.
5Biochemistry Department, National Organization for Research and Control of Biological Product, Egypt.
6Technology of Medical Laboratory, Faculty of Applied Medical Science, Misr University for Science and Technology, Egypt.

Corresponding Author's Email: rehamgabry@gmail.com

Accepted 14th July, 2016.



Abstract


Background: HCV has been identified as the cause of metabolic syndrome, a complex that includes dyslipidemia, diabetes and insulin resistance (IR). Insulin Resistance (IR) index, is a negative predictor of response to interferon-based therapies in patients with HCV. IL28B variations are strongly associated with on-treatment viral kinetics and approximately 2-fold increased sustained virologic response (SVR) rates in HCV genotype 1 and 4 patients, so IL28B gene polymorphism is also considered as a good predictor of treatment response. Aim: To determine the correlation between interleukin 28B genotype and insulin resistance in patients with chronic hepatitis C virus genotype 4 and response to Pegylated interferon and ribavirin treatment. Methods: The study included HCV Patients (n=50) and control patients (n=50). IR was estimated using Homeostasis model assessment (HOMA-IR) = (Serum Insulin (IU/ml)*Serum Glucose (mmol/L) /22.5), viral load was determined by real-time PCR, also SNP assay was done using IL28B polymorphism real time. Results: IL-28 rs12799860 genotypes in HCV patients were as follows; CC genotypes in 58 % (n = 29), CT in 36 % (n = 18) and TT in 6 % (n = 3). The response rate was 86.2 % in CC genotype versus 27.8 % in CT genotype and 2% in TT genotypes which was statistically significant (P=0.001). The correlation between HOMA and response among cases was significantly negative. HOMA-IR >2 was associated with poorer SVR response (39.3% vs. 58.7%; P = 0.007). Conclusion: Results show that IL28B and IR are independent variables associated with SVR for P+R treated patients.

Keywords: IL28B, HOMA, HCV, Gene, Polymorphism, Insulin resistance, Ribavirin, Therapy.

Read: [Full Text - PDF]


Cite This Article:

Ola S. Mohamed, Kamal A. El Atraby, Reham A. Gabry, Khadiga K. EL Gohary, Nahla S. Kotb and Amany A. Abou-Ella. Impact of IL28B Gene Polymorphism and HOMA-IR on Response to Pegylated-interferon and Ribavirin Therapy on Chronic HCV-4 Patients. Donnish Journal of Biomedical Research 3(2) 2015 pp. 006-012.


© 2016 - Donnish Journals | Terms | Privacy policy |